Sumitomo Pharma

Update in progress

4506.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Sumitomo Pharma Co., Ltd. develops, manufactures, purchases, and sells pharmaceutical products for medical treatment across Japan, North America, and Asia. Its portfolio includes therapies for Parkinson’s disease, type 2 diabetes, prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia, plus atypical antipsychotics, generics, antiepileptics, and antibiotics. It also supplies veterinary medicines and medical devices. Based in Osaka, it is a Sumitomo Chemical subsidiary and partners with Otsuka. Formerly Sumitomo Dainippon Pharma, renamed in 2022.

Company score

Sentiment: 0.16; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive